These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 926719)

  • 1. [Action of benzbromarone on the renal excretion of allantoin in normouricemic and hyperuricemic humans (author's transl)].
    Janzen D; Mertz DP; Scheiffele E; Kühnhold O
    Klin Wochenschr; 1977 Nov; 55(21):1071-3. PubMed ID: 926719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of benzbromarone: a new uricosuric drug.
    Sorensen LB; Levinson DJ
    Arthritis Rheum; 1976; 19(2):183-90. PubMed ID: 1259799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of benzbromarone on fasting-hyperuricemia as a model (author's transl)].
    Schräpler P; Kleinschmidt A; Haese E
    Med Klin; 1978 Jun; 73(23):861-6. PubMed ID: 661730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of hypouricemic effect of benzbromarone.
    Sinclair DS; Fox IH
    J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of purine catabolism by benzbromarone in isolated rat liver cells. Comparison with allopurinol and probenecid.
    Rodilla F; Sanchez-Beltran MJ; Izquierdo R; Gomez-Ruiz MD; Cabo J
    Biochem Pharmacol; 1988 Oct; 37(19):3561-3. PubMed ID: 3178870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of benzbromarone and its combination with hydrochlorothiazide on the renal excretion of uric acid and electrolytes].
    Malý J
    Cas Lek Cesk; 1986 Aug; 125(34):1053-6. PubMed ID: 3756994
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of benzbromarone and its combination with hydrochlorothiazide on renal excretion of uric acid and electrolytes.
    Malý J; Schück O
    Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):443-5. PubMed ID: 2258255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal excretion of purine bases. Effects of probenecid, benzbromarone and pyrazinamide.
    Yamamoto T; Moriwaki Y; Takahashi S; Hada T; Higashino K
    Nephron; 1988; 48(2):116-20. PubMed ID: 3344050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
    Schulz E; Schräpler P; Kleinschmidt A
    Med Klin; 1978 Feb; 73(7):240-6. PubMed ID: 628361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypouricemic effect of benzbromarone especially in kidney failure].
    Didier M; Olmer M
    Sem Hop; 1978 Apr; 54(9-12):463-5. PubMed ID: 210519
    [No Abstract]   [Full Text] [Related]  

  • 16. [Variations in fecal elimination of uric acid in 8 patients treated with benzbromarone].
    Dupuich Y; Chandelier C; Niquet G
    LARC Med; 1983 Mar; 3(3):189-90. PubMed ID: 6865603
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
    Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
    Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
    Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
    Yu TF
    J Rheumatol; 1976 Sep; 3(3):305-12. PubMed ID: 978666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.